Using blood tests to improve prognosis and treatment for osteosarcoma
Official title: Liquid biopsy approaches to inform osteosarcoma prognosis and tumor evolution
Funded at Dana-Farber Cancer Inst · NIH-10883604 · Data updated 2026-11-12
This study is looking at how a new blood test can help us understand and improve treatment for kids and young adults with osteosarcoma, a type of bone cancer, by tracking changes in tumor DNA in their blood.
Quick facts
| Grant type | R37 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Dana-Farber Cancer Inst NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project start | July 1, 2020 |
| Project end | June 30, 2025 |
| Funding year | 2024 |
| Award (this year) | $384,644 |
| NIH project number | 5R37CA244355-05 |
| Project ID | NIH-10883604 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include children and young adults diagnosed with osteosarcoma.
✕Less likely to help
Patients with other types of cancer or those who are not diagnosed with osteosarcoma may not benefit from this research.
What this research studies
This research focuses on osteosarcoma, a type of bone cancer that primarily affects children and young adults. It aims to utilize innovative liquid biopsy techniques to analyze circulating tumor DNA (ctDNA) in the blood, which may provide insights into tumor evolution and prognosis. By identifying reliable biomarkers, the study seeks to enhance treatment strategies and outcomes for patients with this aggressive cancer. The approach involves monitoring ctDNA levels to correlate with disease progression and response to therapy.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatment options and improved prognostic tools for patients with osteosarcoma.
How similar studies have gone: Other research has shown promise in using liquid biopsy techniques for various cancers, indicating potential success for this novel approach in osteosarcoma.
Where this research is happening
-
Dana-Farber Cancer Inst
Boston, United States Active
Researchers
- Principal investigator: Crompton, Brian — Dana-Farber Cancer Inst
- Study coordinator: Crompton, Brian
Related research
Other NIH-funded projects on the same topics.
-
Blood test to track and predict neuroblastoma outcomes
This project uses a blood test that looks for tumor DNA signals to help doctors predict outcomes and monitor children with neuroblastoma.
-
Using blood tests to improve prognosis and monitoring of neuroblastoma in children
This study is looking for new ways to use blood tests to help doctors understand how well children with high-risk neuroblastoma are responding to treatment and if they might have a chance of relapse, so they can tailor the best care for each child.
-
Understanding how bone cancer cells rely on certain pathways to grow in childhood osteosarcoma
This grant studies how specific cancer-related pathways in bone-forming cells drive osteosarcoma in children, with the aim of finding better treatments.
-
Histotripsy + immune boost to fight osteosarcoma
A new treatment idea combines a precise non-surgical ultrasound method with an immune-boosting compound to help fight bone cancer in people and dogs.
-
Colorectal cancer prognosis through a broad, collaborative study
A large, multi-center study follows people newly diagnosed with colorectal cancer to find biomarkers and patterns that predict outcomes and guide future care.
-
Genomically guided drug testing for osteosarcoma in patient-derived models
A precision approach tests new drugs on osteosarcoma models created from patients to find promising treatments for kids and teens.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.